CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: LYN (ImmuneEditome ID:4067)

1. Gene summary of enriched editing regions for LYN

check button Gene summary
Gene informationGene symbol

LYN

Gene ID

4067

GeneSynonymsJTK8|SAIDV|p53Lyn|p56Lyn
GeneCytomap

8q12.1

GeneTypeprotein-coding
GeneDescriptiontyrosine-protein kinase Lyn|lck/Yes-related novel protein tyrosine kinase|v-yes-1 Yamaguchi sarcoma viral related oncogene homolog
GeneModificationdate20230527
UniprotIDP07948;E5RJ37
PubMed ID

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr8:55889168-55892230:+ENST00000519728.4ENSG00000254087.6LYNintronicL1MB3,L3,AluJr,AluJb,AluSx3,AluJo,MIR,AluSp,AluSx1chr8:55889168-55892230:+.alignment
chr8:55889168-55892230:+ENST00000520220.5ENSG00000254087.6LYNintronicL1MB3,L3,AluJr,AluJb,AluSx3,AluJo,MIR,AluSp,AluSx1chr8:55889168-55892230:+.alignment
chr8:55897613-55898547:+ENST00000519728.4ENSG00000254087.6LYNintronicAluJb,AluSz,L1ME1chr8:55897613-55898547:+.alignment
chr8:55897613-55898547:+ENST00000520220.5ENSG00000254087.6LYNintronicAluJb,AluSz,L1ME1chr8:55897613-55898547:+.alignment
chr8:55903710-55903915:+ENST00000519728.4ENSG00000254087.6LYNintronicAluJbchr8:55903710-55903915:+.alignment
chr8:55903710-55903915:+ENST00000520220.5ENSG00000254087.6LYNintronicAluJbchr8:55903710-55903915:+.alignment
chr8:55905232-55907756:+ENST00000519728.4ENSG00000254087.6LYNintronicL1ME2,(AG)n,AluSx1,AluJo,AluJr,(GTTTT)n,AluSq2chr8:55905232-55907756:+.alignment
chr8:55905232-55907756:+ENST00000520220.5ENSG00000254087.6LYNintronicL1ME2,(AG)n,AluSx1,AluJo,AluJr,(GTTTT)n,AluSq2chr8:55905232-55907756:+.alignment
chr8:55916873-55917382:+ENST00000519728.4ENSG00000254087.6LYNintronicAluSz6,AluJochr8:55916873-55917382:+.alignment
chr8:55916873-55917382:+ENST00000520220.5ENSG00000254087.6LYNintronicAluSz6,AluJochr8:55916873-55917382:+.alignment
chr8:55922104-55922736:+ENST00000519728.4ENSG00000254087.6LYNintronicAluSq,AluJbchr8:55922104-55922736:+.alignment
chr8:55922104-55922736:+ENST00000520220.5ENSG00000254087.6LYNintronicAluSq,AluJbchr8:55922104-55922736:+.alignment
chr8:55977632-55977917:+ENST00000420292.1ENSG00000254087.6LYNncRNA_intronicAluJrchr8:55977632-55977917:+.alignment
chr8:55985869-55987699:+ENST00000420292.1ENSG00000254087.6LYNncRNA_intronicAluSx1,L1M3,AluJb,AluJrchr8:55985869-55987699:+.alignment
chr8:56002503-56003705:+ENST00000519728.4ENSG00000254087.6LYNintronicAluY,AluSz6,AluSx,Tigger10,(AAATT)nchr8:56002503-56003705:+.alignment
chr8:56002503-56003705:+ENST00000520220.5ENSG00000254087.6LYNintronicAluY,AluSz6,AluSx,Tigger10,(AAATT)nchr8:56002503-56003705:+.alignment
chr8:56004875-56005995:+ENST00000519728.4ENSG00000254087.6LYNintronicL1M7,AluJr,AluJr4,L1MB3chr8:56004875-56005995:+.alignment
chr8:56004875-56005995:+ENST00000520220.5ENSG00000254087.6LYNintronicL1M7,AluJr,AluJr4,L1MB3chr8:56004875-56005995:+.alignment
chr8:56013363-56013581:+ENST00000520220.5ENSG00000254087.6LYNUTR3AluSxchr8:56013363-56013581:+.alignment


Top

2. Tumor-specific enriched editing regions for LYN


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot
ENSG00000254087.6,LYNLUADPathEAG1.2118e-022.8021e-030.5940image


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot

Top

3. Enriched editing regions and immune related genes for LYN


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr8:55897613-55898547:+LAMLEERENSG00000254325,RP11-318K15.2-0.48145.5601e-043.8195e-07-0.4081imageNNNAMonocytesGSVA_HALLMARK_DNA_REPAIR
chr8:55897613-55898547:+LAMLEERENSG00000215252,GOLGA8B0.41936.0326e-035.1331e-090.4630imageNNNAEosinophilsGSVA_HALLMARK_INFLAMMATORY_RESPONSE
chr8:55897613-55898547:+LAMLEERENSG00000165948,IFI27L10.41068.0612e-033.9307e-090.4661imageNNIFI27L1MonocytesGSVA_HALLMARK_DNA_REPAIR
chr8:55897613-55898547:+LAMLEERENSG00000188878,FBF10.37641.9076e-023.4655e-070.4095imageNNFBF1MonocytesGSVA_HALLMARK_DNA_REPAIR
chr8:55897613-55898547:+LAMLEERENSG00000175265,GOLGA8A0.34543.7730e-025.8553e-070.4021imageNNNAEosinophilsGSVA_HALLMARK_KRAS_SIGNALING_UP
chr8:55897613-55898547:+LAMLEERENSG00000254325,RP11-318K15.2-0.48145.5601e-043.8195e-07-0.4081imageNNNAMonocytesGSVA_HALLMARK_DNA_REPAIR
chr8:55897613-55898547:+LAMLEERENSG00000215252,GOLGA8B0.41936.0326e-035.1331e-090.4630imageNNNAEosinophilsGSVA_HALLMARK_INFLAMMATORY_RESPONSE
chr8:55897613-55898547:+LAMLEERENSG00000165948,IFI27L10.41068.0612e-033.9307e-090.4661imageNNIFI27L1MonocytesGSVA_HALLMARK_DNA_REPAIR
chr8:55897613-55898547:+LAMLEERENSG00000188878,FBF10.37641.9076e-023.4655e-070.4095imageNNFBF1MonocytesGSVA_HALLMARK_DNA_REPAIR
chr8:55897613-55898547:+LAMLEERENSG00000175265,GOLGA8A0.34543.7730e-025.8553e-070.4021imageNNNAEosinophilsGSVA_HALLMARK_KRAS_SIGNALING_UP
chr8:55903710-55903915:+LAMLEERENSG00000137845,ADAM10-0.43935.9285e-031.9823e-06-0.4017imageNNADAM10MonocytesGSVA_HALLMARK_PROTEIN_SECRETION
chr8:55903710-55903915:+LAMLEERENSG00000137845,ADAM10-0.43935.9285e-031.9823e-06-0.4017imageNNADAM10MonocytesGSVA_HALLMARK_PROTEIN_SECRETION
chr8:55916873-55917382:+LAMLEERENSG00000084733,RAB10-0.47643.4868e-031.7138e-06-0.4224imageNNNAMonocytesGSVA_HALLMARK_PROTEIN_SECRETION
chr8:55916873-55917382:+LAMLEERENSG00000112624,GLTSCR1L-0.43251.1753e-028.0147e-10-0.5261imageNNNAT_cells_CD4_memory_restingGSVA_HALLMARK_GLYCOLYSIS
chr8:55916873-55917382:+LAMLEERENSG00000124151,NCOA3-0.42951.3035e-021.4414e-06-0.4251imageNNNAMonocytesGSVA_HALLMARK_DNA_REPAIR
chr8:55916873-55917382:+LAMLEERENSG00000171940,ZNF217-0.42331.4551e-023.2585e-06-0.4119imageNNNAMonocytesGSVA_HALLMARK_PROTEIN_SECRETION
chr8:55916873-55917382:+LAMLEERENSG00000100934,SEC23A-0.42041.5812e-022.8784e-06-0.4139imageNNNAPlasma_cellsGSVA_HALLMARK_PROTEIN_SECRETION
chr8:55916873-55917382:+LAMLEERENSG00000135390,ATP5G20.41521.7799e-024.5263e-070.4430imageNNNANK_cells_activatedGSVA_HALLMARK_PROTEIN_SECRETION
chr8:55916873-55917382:+LAMLEERENSG00000115145,STAM2-0.40571.9737e-022.0545e-06-0.4194imageNNNAT_cells_CD8GSVA_HALLMARK_MYOGENESIS
chr8:55916873-55917382:+LAMLEERENSG00000161533,ACOX1-0.39642.3911e-022.7889e-06-0.4144imageNNACOX1NeutrophilsGSVA_HALLMARK_PROTEIN_SECRETION
chr8:55916873-55917382:+LAMLEERENSG00000147251,DOCK11-0.39892.5332e-024.2788e-07-0.4439imageNNDOCK11Plasma_cellsGSVA_HALLMARK_DNA_REPAIR
chr8:55916873-55917382:+LAMLEERENSG00000147123,NDUFB110.38353.4225e-022.6696e-080.4829imageNNNAMast_cells_activatedGSVA_HALLMARK_DNA_REPAIR
chr8:55916873-55917382:+LAMLEERENSG00000084733,RAB10-0.47643.4868e-031.7138e-06-0.4224imageNNNAMonocytesGSVA_HALLMARK_PROTEIN_SECRETION
chr8:55916873-55917382:+LAMLEERENSG00000112624,GLTSCR1L-0.43251.1753e-028.0147e-10-0.5261imageNNNAT_cells_CD4_memory_restingGSVA_HALLMARK_GLYCOLYSIS
chr8:55916873-55917382:+LAMLEERENSG00000124151,NCOA3-0.42951.3035e-021.4414e-06-0.4251imageNNNAMonocytesGSVA_HALLMARK_DNA_REPAIR
chr8:55916873-55917382:+LAMLEERENSG00000171940,ZNF217-0.42331.4551e-023.2585e-06-0.4119imageNNNAMonocytesGSVA_HALLMARK_PROTEIN_SECRETION
chr8:55916873-55917382:+LAMLEERENSG00000100934,SEC23A-0.42041.5812e-022.8784e-06-0.4139imageNNNAPlasma_cellsGSVA_HALLMARK_PROTEIN_SECRETION
chr8:55916873-55917382:+LAMLEERENSG00000135390,ATP5G20.41521.7799e-024.5263e-070.4430imageNNNANK_cells_activatedGSVA_HALLMARK_PROTEIN_SECRETION
chr8:55916873-55917382:+LAMLEERENSG00000115145,STAM2-0.40571.9737e-022.0545e-06-0.4194imageNNNAT_cells_CD8GSVA_HALLMARK_MYOGENESIS
chr8:55916873-55917382:+LAMLEERENSG00000161533,ACOX1-0.39642.3911e-022.7889e-06-0.4144imageNNACOX1NeutrophilsGSVA_HALLMARK_PROTEIN_SECRETION
chr8:55916873-55917382:+LAMLEERENSG00000147251,DOCK11-0.39892.5332e-024.2788e-07-0.4439imageNNDOCK11Plasma_cellsGSVA_HALLMARK_DNA_REPAIR
chr8:55916873-55917382:+LAMLEERENSG00000147123,NDUFB110.38353.4225e-022.6696e-080.4829imageNNNAMast_cells_activatedGSVA_HALLMARK_DNA_REPAIR
chr8:55922104-55922736:+LAMLEERENSG00000132591,ERAL10.39102.4734e-025.0402e-070.4284imageNNNAT_cells_regulatory_(Tregs)GSVA_HALLMARK_DNA_REPAIR
chr8:55922104-55922736:+LAMLEERENSG00000132591,ERAL10.39102.4734e-025.0402e-070.4284imageNNNAT_cells_regulatory_(Tregs)GSVA_HALLMARK_DNA_REPAIR

More results



Top

4. Enriched editing regions and immune related splicing for LYN


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark

More results



Top

5. Enriched editing regions and immune infiltration for LYN


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
chr8:55889168-55892230:+ESCAEERB_cells_memory2.8635e-020.4137image
ENSG00000254087.6,LYNESCAEAGDendritic_cells_activated4.6284e-030.2681image
chr8:55897613-55898547:+LAMLEERT_cells_follicular_helper9.0028e-040.2738image
chr8:55903710-55903915:+LAMLEERNK_cells_activated1.1269e-020.2208image
chr8:55905232-55907756:+LAMLEERB_cells_naive4.7910e-040.3009image
chr8:55922104-55922736:+LAMLEERPlasma_cells4.9736e-040.3046image
chr8:55985869-55987699:+LAMLEERMacrophages_M21.7150e-030.3024image
chr8:56004875-56005995:+LAMLEERT_cells_CD4_memory_activated3.3686e-02-0.2639image
ENSG00000254087.6,LYNLAMLEAGMonocytes1.2829e-05-0.3502image
ENSG00000254087.6,LYNOVEAGEosinophils6.2515e-050.6472image
chr8:55897613-55898547:+STADEERT_cells_CD4_memory_activated3.2622e-020.4675image
chr8:55905232-55907756:+STADEERNK_cells_resting2.5663e-030.2260image
chr8:55916873-55917382:+STADEERMast_cells_activated1.6454e-02-0.3281image
chr8:55977632-55977917:+STADEERMacrophages_M01.9415e-020.2659image
chr8:56002503-56003705:+STADEERT_cells_CD82.4558e-020.4576image
ENSG00000254087.6,LYNSTADEAGMacrophages_M27.6467e-030.1786image


Top

6. Enriched editing regions and immune gene sets for LYN


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot
ENSG00000254087.6,LYNSTADEAG5.0950e-040.23141.3137e-030.21431.4156e-020.16451.0155e-030.2191image


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
chr8:55889168-55892230:+ESCAGSVA_HALLMARK_HEDGEHOG_SIGNALINGEER2.6027e-03-0.5468image
ENSG00000254087.6,LYNESCAGSVA_HALLMARK_HYPOXIAEAG1.1398e-020.2404image
chr8:55916873-55917382:+LAMLGSVA_HALLMARK_PROTEIN_SECRETIONEER3.5484e-03-0.2653image
chr8:56004875-56005995:+LAMLGSVA_HALLMARK_SPERMATOGENESISEER2.5197e-050.4972image
chr8:55905232-55907756:+LAMLGSVA_HALLMARK_E2F_TARGETSEER3.9831e-020.1798image
ENSG00000254087.6,LYNLAMLGSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKBEAG1.5643e-04-0.3059image
chr8:55903710-55903915:+LAMLGSVA_HALLMARK_PROTEIN_SECRETIONEER6.9121e-03-0.2349image
chr8:55922104-55922736:+LAMLGSVA_HALLMARK_DNA_REPAIREER2.8773e-030.2624image
chr8:55897613-55898547:+LAMLGSVA_HALLMARK_DNA_REPAIREER9.5671e-030.2153image
ENSG00000254087.6,LYNOVGSVA_HALLMARK_DNA_REPAIREAG2.9062e-020.3861image
chr8:55897613-55898547:+STADGSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSEEER8.7935e-040.6705image
chr8:55977632-55977917:+STADGSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSEEER4.9980e-020.2242image
chr8:55905232-55907756:+STADGSVA_HALLMARK_APOPTOSISEER1.0560e-050.3253image
ENSG00000254087.6,LYNSTADGSVA_HALLMARK_PI3K_AKT_MTOR_SIGNALINGEAG4.0074e-060.3038image


Top

7. Enriched editing regions and drugs for LYN


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
chr8:55889168-55892230:+ESCACGP.60474EER3.5191e-020.3995image
ENSG00000254087.6,LYNESCAJW.7.52.1EAG4.3829e-03-0.2697image
chr8:55916873-55917382:+LAMLBMS.509744EER4.8839e-07-0.4419image
chr8:56004875-56005995:+LAMLA.443654EER3.4661e-04-0.4303image
chr8:55905232-55907756:+LAMLCI.1040EER1.8658e-020.2053image
ENSG00000254087.6,LYNLAMLCMKEAG6.2538e-07-0.3961image
chr8:55903710-55903915:+LAMLGW843682XEER4.5443e-04-0.3021image
chr8:55922104-55922736:+LAMLA.443654EER4.3104e-04-0.3078image
chr8:55897613-55898547:+LAMLBI.2536EER6.3510e-05-0.3269image
chr8:55985869-55987699:+LAMLErlotinibEER2.1543e-03-0.2962image
chr8:55889168-55892230:+LAMLAZD6244EER3.6994e-03-0.2529image
ENSG00000254087.6,LYNOVMG.132EAG3.2683e-02-0.3785image
chr8:55897613-55898547:+STADCCT007093EER3.3160e-020.4662image
chr8:55889168-55892230:+STADElesclomolEER2.3583e-03-0.3333image
chr8:55916873-55917382:+STADGW843682XEER2.7165e-02-0.3035image
chr8:55977632-55977917:+STADCyclopamineEER3.0267e-02-0.2487image
chr8:55905232-55907756:+STADLFM.A13EER4.2469e-030.2145image
ENSG00000254087.6,LYNSTADGemcitabineEAG6.6661e-04-0.2267image
chr8:56002503-56003705:+STADAG.014699EER4.8706e-020.4065image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType
chr8:55889168-55892230:+ENST00000519728.4P07948DB01254DasatinibSmallMoleculeDrug
chr8:55889168-55892230:+ENST00000519728.4P07948DB06616BosutinibSmallMoleculeDrug
chr8:55889168-55892230:+ENST00000519728.4P07948DB08901PonatinibSmallMoleculeDrug
chr8:55889168-55892230:+ENST00000519728.4P07948DB09079NintedanibSmallMoleculeDrug
chr8:55889168-55892230:+ENST00000519728.4P07948DB12010FostamatinibSmallMoleculeDrug
chr8:55889168-55892230:+ENST00000520220.5P07948DB01254DasatinibSmallMoleculeDrug
chr8:55889168-55892230:+ENST00000520220.5P07948DB06616BosutinibSmallMoleculeDrug
chr8:55889168-55892230:+ENST00000520220.5P07948DB08901PonatinibSmallMoleculeDrug
chr8:55889168-55892230:+ENST00000520220.5P07948DB09079NintedanibSmallMoleculeDrug
chr8:55889168-55892230:+ENST00000520220.5P07948DB12010FostamatinibSmallMoleculeDrug
chr8:55897613-55898547:+ENST00000519728.4P07948DB01254DasatinibSmallMoleculeDrug
chr8:55897613-55898547:+ENST00000519728.4P07948DB06616BosutinibSmallMoleculeDrug
chr8:55897613-55898547:+ENST00000519728.4P07948DB08901PonatinibSmallMoleculeDrug
chr8:55897613-55898547:+ENST00000519728.4P07948DB09079NintedanibSmallMoleculeDrug
chr8:55897613-55898547:+ENST00000519728.4P07948DB12010FostamatinibSmallMoleculeDrug
chr8:55897613-55898547:+ENST00000520220.5P07948DB01254DasatinibSmallMoleculeDrug
chr8:55897613-55898547:+ENST00000520220.5P07948DB06616BosutinibSmallMoleculeDrug
chr8:55897613-55898547:+ENST00000520220.5P07948DB08901PonatinibSmallMoleculeDrug
chr8:55897613-55898547:+ENST00000520220.5P07948DB09079NintedanibSmallMoleculeDrug
chr8:55897613-55898547:+ENST00000520220.5P07948DB12010FostamatinibSmallMoleculeDrug
chr8:55903710-55903915:+ENST00000519728.4P07948DB01254DasatinibSmallMoleculeDrug
chr8:55903710-55903915:+ENST00000519728.4P07948DB06616BosutinibSmallMoleculeDrug
chr8:55903710-55903915:+ENST00000519728.4P07948DB08901PonatinibSmallMoleculeDrug
chr8:55903710-55903915:+ENST00000519728.4P07948DB09079NintedanibSmallMoleculeDrug
chr8:55903710-55903915:+ENST00000519728.4P07948DB12010FostamatinibSmallMoleculeDrug
chr8:55903710-55903915:+ENST00000520220.5P07948DB01254DasatinibSmallMoleculeDrug
chr8:55903710-55903915:+ENST00000520220.5P07948DB06616BosutinibSmallMoleculeDrug
chr8:55903710-55903915:+ENST00000520220.5P07948DB08901PonatinibSmallMoleculeDrug
chr8:55903710-55903915:+ENST00000520220.5P07948DB09079NintedanibSmallMoleculeDrug
chr8:55903710-55903915:+ENST00000520220.5P07948DB12010FostamatinibSmallMoleculeDrug
chr8:55905232-55907756:+ENST00000519728.4P07948DB01254DasatinibSmallMoleculeDrug
chr8:55905232-55907756:+ENST00000519728.4P07948DB06616BosutinibSmallMoleculeDrug
chr8:55905232-55907756:+ENST00000519728.4P07948DB08901PonatinibSmallMoleculeDrug
chr8:55905232-55907756:+ENST00000519728.4P07948DB09079NintedanibSmallMoleculeDrug
chr8:55905232-55907756:+ENST00000519728.4P07948DB12010FostamatinibSmallMoleculeDrug
chr8:55905232-55907756:+ENST00000520220.5P07948DB01254DasatinibSmallMoleculeDrug
chr8:55905232-55907756:+ENST00000520220.5P07948DB06616BosutinibSmallMoleculeDrug
chr8:55905232-55907756:+ENST00000520220.5P07948DB08901PonatinibSmallMoleculeDrug
chr8:55905232-55907756:+ENST00000520220.5P07948DB09079NintedanibSmallMoleculeDrug
chr8:55905232-55907756:+ENST00000520220.5P07948DB12010FostamatinibSmallMoleculeDrug
chr8:55916873-55917382:+ENST00000519728.4P07948DB01254DasatinibSmallMoleculeDrug
chr8:55916873-55917382:+ENST00000519728.4P07948DB06616BosutinibSmallMoleculeDrug
chr8:55916873-55917382:+ENST00000519728.4P07948DB08901PonatinibSmallMoleculeDrug
chr8:55916873-55917382:+ENST00000519728.4P07948DB09079NintedanibSmallMoleculeDrug
chr8:55916873-55917382:+ENST00000519728.4P07948DB12010FostamatinibSmallMoleculeDrug
chr8:55916873-55917382:+ENST00000520220.5P07948DB01254DasatinibSmallMoleculeDrug
chr8:55916873-55917382:+ENST00000520220.5P07948DB06616BosutinibSmallMoleculeDrug
chr8:55916873-55917382:+ENST00000520220.5P07948DB08901PonatinibSmallMoleculeDrug
chr8:55916873-55917382:+ENST00000520220.5P07948DB09079NintedanibSmallMoleculeDrug
chr8:55916873-55917382:+ENST00000520220.5P07948DB12010FostamatinibSmallMoleculeDrug
chr8:55922104-55922736:+ENST00000519728.4P07948DB01254DasatinibSmallMoleculeDrug
chr8:55922104-55922736:+ENST00000519728.4P07948DB06616BosutinibSmallMoleculeDrug
chr8:55922104-55922736:+ENST00000519728.4P07948DB08901PonatinibSmallMoleculeDrug
chr8:55922104-55922736:+ENST00000519728.4P07948DB09079NintedanibSmallMoleculeDrug
chr8:55922104-55922736:+ENST00000519728.4P07948DB12010FostamatinibSmallMoleculeDrug
chr8:55922104-55922736:+ENST00000520220.5P07948DB01254DasatinibSmallMoleculeDrug
chr8:55922104-55922736:+ENST00000520220.5P07948DB06616BosutinibSmallMoleculeDrug
chr8:55922104-55922736:+ENST00000520220.5P07948DB08901PonatinibSmallMoleculeDrug
chr8:55922104-55922736:+ENST00000520220.5P07948DB09079NintedanibSmallMoleculeDrug
chr8:55922104-55922736:+ENST00000520220.5P07948DB12010FostamatinibSmallMoleculeDrug
chr8:56002503-56003705:+ENST00000519728.4P07948DB01254DasatinibSmallMoleculeDrug
chr8:56002503-56003705:+ENST00000519728.4P07948DB06616BosutinibSmallMoleculeDrug
chr8:56002503-56003705:+ENST00000519728.4P07948DB08901PonatinibSmallMoleculeDrug
chr8:56002503-56003705:+ENST00000519728.4P07948DB09079NintedanibSmallMoleculeDrug
chr8:56002503-56003705:+ENST00000519728.4P07948DB12010FostamatinibSmallMoleculeDrug
chr8:56002503-56003705:+ENST00000520220.5P07948DB01254DasatinibSmallMoleculeDrug
chr8:56002503-56003705:+ENST00000520220.5P07948DB06616BosutinibSmallMoleculeDrug
chr8:56002503-56003705:+ENST00000520220.5P07948DB08901PonatinibSmallMoleculeDrug
chr8:56002503-56003705:+ENST00000520220.5P07948DB09079NintedanibSmallMoleculeDrug
chr8:56002503-56003705:+ENST00000520220.5P07948DB12010FostamatinibSmallMoleculeDrug
chr8:56004875-56005995:+ENST00000519728.4P07948DB01254DasatinibSmallMoleculeDrug
chr8:56004875-56005995:+ENST00000519728.4P07948DB06616BosutinibSmallMoleculeDrug
chr8:56004875-56005995:+ENST00000519728.4P07948DB08901PonatinibSmallMoleculeDrug
chr8:56004875-56005995:+ENST00000519728.4P07948DB09079NintedanibSmallMoleculeDrug
chr8:56004875-56005995:+ENST00000519728.4P07948DB12010FostamatinibSmallMoleculeDrug
chr8:56004875-56005995:+ENST00000520220.5P07948DB01254DasatinibSmallMoleculeDrug
chr8:56004875-56005995:+ENST00000520220.5P07948DB06616BosutinibSmallMoleculeDrug
chr8:56004875-56005995:+ENST00000520220.5P07948DB08901PonatinibSmallMoleculeDrug
chr8:56004875-56005995:+ENST00000520220.5P07948DB09079NintedanibSmallMoleculeDrug
chr8:56004875-56005995:+ENST00000520220.5P07948DB12010FostamatinibSmallMoleculeDrug
chr8:56013363-56013581:+ENST00000520220.5P07948DB01254DasatinibSmallMoleculeDrug
chr8:56013363-56013581:+ENST00000520220.5P07948DB06616BosutinibSmallMoleculeDrug
chr8:56013363-56013581:+ENST00000520220.5P07948DB08901PonatinibSmallMoleculeDrug
chr8:56013363-56013581:+ENST00000520220.5P07948DB09079NintedanibSmallMoleculeDrug
chr8:56013363-56013581:+ENST00000520220.5P07948DB12010FostamatinibSmallMoleculeDrug